Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Forma Therapeutics Holdings, Inc.

(Name of Subject Company)

 

 

Forma Therapeutics Holdings, Inc.

(Name of Persons Filing Statement)

 

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

34633R104

(CUSIP Number of Class of Securities)

Frank D. Lee

Forma Therapeutics Holdings, Inc.

President & Chief Executive Officer

300 North Beacon Street

Suite 501

Watertown, Massachusetts 02472

[phone]

With copies to:

Stuart M. Cable, Esq.

Lisa R. Haddad, Esq.

William D. Collins, Esq.

Andrew H. Goodman, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

[phone]

(Name, address, and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)

 

 

 

☒

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Forma Therapeutics Holdings, Inc. on September 1, 2022 (including all exhibits attached thereto) is incorporated herein by reference.